<DOC>
	<DOCNO>NCT00926120</DOCNO>
	<brief_summary>The purpose study determine administer Mogroside Sweetener `` PureLo '' ( study substance ) 14 day low hepatitis C viral load liver function alanine aminotransferase ( ALT ) level .</brief_summary>
	<brief_title>The Effects Mogroside Sweetener Viral Load TreatmenT Naive Genotype 1 ( GT 1 ) Subjects CHC</brief_title>
	<detailed_description>The primary objective study assess safety efficacy administer Mogroside Sweetener `` PureLo '' genotype 1 subject dose level 5 gram every 6 hour 14 day hepatitis C viral load serum ALT level . Percentage change HCV load first 48 hour daily 14 day change serum ALT level two week period study , calculate patient . The number subject show decline viral load least 50 % calculate , number subject decrease serum ALT level least 50 % . All efficacy safety analysis conduct end study .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<criteria>Serologic evidence HVC infection antiHCV antibody test . Serum HCV RNA quantifiable &gt; 20,000 copies/mL screen period demonstrate abnormal ALT &gt; 40 6 month . No clinical suspicion radiological evidence hepatocellular carcinoma serum AFP &lt; 50 ng/mL . Negative urine pregnancy test woman childbearing potential document within 24hour period prior first dose test drug . Interferon without RBV therapy previous time systemic antiviral therapy investigational drug &gt; 3 month prior first dose study drug . Subjects expect need systemic antiviral therapy time study also exclude . Positive test screen antiHAV 1gM Ab , HbsAg , antiHBc IgM Ab , antiHIV Ab . Documented serum concentration ceruloplasmin Alpha 1antitrypsin consistent increase risk metabolic liver disease . History evidence medical condition associate chronic liver disease ( e.g. , haemochromatosis , autoimmune hepatitis , alcoholic liver disease , toxin exposure ) . Women ongoing pregnancy breast feed Neutrophil count &lt; 1000 cells/mm3 , Hgb &lt; 11 g/dL woman 12 g/dL men , platelet count &lt; 80,000 cells/mm3 . Serum creatinine level &gt; 2 time upper limit normal screening . Evidence alcohol and/or drug abuse within one year entry . History severe psychiatric disease , especially depression . Severe psychiatric disease define treatment antidepressant medication major tranquillizer therapeutic dos major depression psychosis , respectively , least 4 month previous time history follow : suicidal attempt hospitalization psychiatric disease , OR period disability due psychiatric disease . History immunologically mediate disease ( e.g. , inflammatory bowel disease , idiopathic thrombocytopenic purpura , lupus erythematous , autoimmune hemolytic anemia , scleroderma , severe psoriasis , sarcoidosis , etc. ) . History evidence bleed esophageal varix condition consistent decompensated liver disease include ascites hepatic encephalopathy . History evidence chronic pulmonary disease associate functional limitation . History severe cardiac disease . History severe seizure disorder current anticonvulsant use . Evidence active suspect cancer past history malignancy skin cancer . History receive systemic antineoplastic immunomodulatory treatment ( include supraphysiologic dos steroid radiation ) â‰¤ 6 month prior first dose study drug expectation treatment need time study . History major organ transplantation exist functional graft . History thyroid disease poorly control prescribed medication . History evidence severe retinopathy . Inability unwillingness provide inform consent abide requirement study . History evidence severe illness condition would make patient , opinion investigator , unsuitable study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>Chronic Hepatitis C</keyword>
</DOC>